Warning: The NCBI web site requires JavaScript to function. more...
Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics.
Wilken JA, Webster KT, Maihle NJ.
J Ovarian Res. 2010 Mar 27;3:7.
Related citations
Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells.
Narayan M, Wilken JA, Harris LN, Baron AT, Kimbler KD, Maihle NJ.
Cancer Res. 2009 Mar 15;69(6):2191-4. Epub 2009 Mar 10.
Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
Menendez JA, Vellon L, Lupu R.
Med Hypotheses. 2005;64(5):997-1001.
Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation.
Brockhoff G, Heckel B, Schmidt-Bruecken E, Plander M, Hofstaedter F, Vollmann A, Diermeier S.
Cell Prolif. 2007 Aug;40(4):488-507.
Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network.
Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA, Arteaga CL.
Clin Cancer Res. 2007 Aug 15;13(16):4909-19.
EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.
Dua R, Zhang J, Nhonthachit P, Penuel E, Petropoulos C, Parry G.
Breast Cancer Res Treat. 2010 Aug;122(3):685-97. Epub 2009 Oct 27.
Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A, Colomer R, Brunet J, Menendez JA.
Int J Oncol. 2007 Oct;31(4):769-76.
Progression and treatment of HER2-positive breast cancer.
Davoli A, Hocevar BA, Brown TL.
Cancer Chemother Pharmacol. 2010 Mar;65(4):611-23. Epub 2009 Dec 20.
Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells.
Xu H, Yu Y, Marciniak D, Rishi AK, Sarkar FH, Kucuk O, Majumdar AP.
Mol Cancer Ther. 2005 Mar;4(3):435-42.
Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts.
du Manoir JM, Francia G, Man S, Mossoba M, Medin JA, Viloria-Petit A, Hicklin DJ, Emmenegger U, Kerbel RS.
Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):904-16.
Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells.
Reim F, Dombrowski Y, Ritter C, Buttmann M, Häusler S, Ossadnik M, Krockenberger M, Beier D, Beier CP, Dietl J, Becker JC, Hönig A, Wischhusen J.
Cancer Res. 2009 Oct 15;69(20):8058-66. Epub 2009 Oct 13.
Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
Chan CT, Metz MZ, Kane SE.
Breast Cancer Res Treat. 2005 May;91(2):187-201.
Cooperative cell-growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer.
Nakamura H, Takamori S, Fujii T, Ono M, Yamana H, Kuwano M, Shirouzu K.
Cancer Lett. 2005 Dec 8;230(1):33-46. Epub 2005 Jan 20.
Inhibition of functional HER family members increases the sensitivity to docetaxel in human ovarian cancer cell lines.
Bijman MN, van Berkel MP, Kok M, Janmaat ML, Boven E.
Anticancer Drugs. 2009 Jul;20(6):450-60.
The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
Raben D, Helfrich B, Chan DC, Ciardiello F, Zhao L, Franklin W, Barón AE, Zeng C, Johnson TK, Bunn PA Jr.
Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):795-805.
Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies.
Faratian D, Zweemer AJ, Nagumo Y, Sims AH, Muir M, Dodds M, Mullen P, Um I, Kay C, Hasmann M, Harrison DJ, Langdon SP.
Clin Cancer Res. 2011 Jul 1;17(13):4451-61. Epub 2011 May 13.
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.
Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC, Slamon DJ.
Cancer Res. 2006 Feb 1;66(3):1630-9.
Primary trastuzumab resistance: new tricks for an old drug.
Wilken JA, Maihle NJ.
Ann N Y Acad Sci. 2010 Oct;1210:53-65. doi: 10.1111/j.1749-6632.2010.05782.x.
The role of trastuzumab in early stage breast cancer: current data and treatment recommendations.
Lin A, Rugo HS.
Curr Treat Options Oncol. 2007 Feb;8(1):47-60. Review.
Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Ann Oncol. 2005 Aug;16(8):1253-67. Epub 2005 May 3.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on